Schonfeld Strategic Advisors’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$48.2K	Buy	+20,600	New	+$53.2K	﹤0.01%	1969
2023 Q4	–	Sell	-14,900	Closed	-$299K	–	2281
2023 Q3	$299K	Buy	+14,900	New	+$378K	﹤0.01%	1327
2022 Q1	–	Sell	-8,600	Closed	-$723K	–	2970
2021 Q4	$723K	Sell	8,600 -20,687	-71%	-$1.6M	0.01%	1097
2021 Q3	$1.95M	Buy	29,287 +8,451	+41%	+$488K	0.02%	725
2021 Q2	$1.11M	Buy	+20,836	New	+$1.12M	0.01%	898

Other funds holding ZNTL

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Schonfeld Strategic Advisors's ZNTL Position: Q1 2026 in Review

Schonfeld Strategic Advisors opened a new position in Zentalis Pharmaceuticals (ZNTL) in Q1 2026: 20,600 shares worth $48.2K. The stake represents ﹤0.01% of the portfolio and ranks #1969 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in ZNTL as recently as Q3 2023.

Schonfeld Strategic Advisors first reported a position in ZNTL in Q2 2021 and has held it in 5 quarters since. The position peaked at $1.95M in Q3 2021. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

Schonfeld Strategic Advisors held 20,600 shares of Zentalis Pharmaceuticals worth $48.2K as of Q1 2026.
Zentalis Pharmaceuticals was a new Schonfeld Strategic Advisors position in Q1 2026.
Zentalis Pharmaceuticals made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #1969 holding.
Schonfeld Strategic Advisors first reported a position in Zentalis Pharmaceuticals in Q2 2021 and has held it in 5 quarters since.
Schonfeld Strategic Advisors's Zentalis Pharmaceuticals position peaked at $1.95M in Q3 2021.
102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.